LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill

Core Viewpoint - LifeMD, Inc. has expanded its virtual weight management offerings by introducing Novo Nordisk's Wegovy pill, the first FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health, available for eligible patients at a starting price of $149 per month [1][5]. Group 1: Product Offering - LifeMD is now offering Wegovy (semaglutide) through its telehealth platform, enhancing access to affordable branded treatment options for weight management [1]. - Wegovy is indicated for reducing excess body weight, supporting long-term weight maintenance, and lowering the risk of major adverse cardiovascular events, with a Phase 3 trial showing a mean weight loss of 16.6% compared to 2.7% with placebo [3]. - The oral formulation of Wegovy is expected to attract patients who are hesitant to use injectable treatments, thereby broadening access to GLP-1 therapies [3]. Group 2: Collaboration and Integration - LifeMD's collaboration with Novo Nordisk is highlighted, with LifeMD being featured as a trusted telehealth provider on NovoCare and Wegovy websites, reflecting the demand for convenient access to GLP-1 therapies [2]. - The integration with NovoCare Pharmacy allows streamlined access to both injectable and oral GLP-1 medications, including Wegovy and Ozempic, at competitive cash-pay pricing [4]. - LifeMD provides a comprehensive experience that includes virtual visits, ongoing clinical oversight, diagnostic testing, pharmacy fulfillment, and simplified billing [4]. Group 3: Pricing and Availability - Wegovy 1.5mg and 4mg pills are available for $149 per month, with future pricing adjustments planned for April 15, 2026, where 4mg will be priced at $199 and higher doses at $299 per month [5].